Janux Therapeutics Inc — Cash Flow (NASDAQ:JANX) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Cash from operating activities 16.98 M42.92 M50.58 M43.81 M82.23 M 82.23 M Cash from investing activities 340.96 M58.27 M41.19 M258.02 M300.98 M 300.98 M Cash from financing activities 386.52 M500 K59.55 M713.24 M4.95 M 4.95 M Free cash flow 15.49 M36.48 M48.73 M43.45 M81.19 M 81.19 M

Notizie

Janux therapeutics doses first participant in JANX011 phase 1 trial

Vir Biotechnology Stock: The Low-Down On The Readouts Ahead (NASDAQ:VIR)

Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?

Janux Therapeutics nomina William Go come nuovo direttore medico

Janux Therapeutics appoints William Go as new chief medical officer

Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion (BMY)

JANX Enters Global Oncology Collaboration With BMY, Stock Rises

Il titolo Janux sale dopo l’accordo di collaborazione con Bristol Myers Squibb

Janux stock rises after Bristol Myers Squibb collaboration deal

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Janux Therapeutics (NASDAQ:JANX)

Le azioni di Janux Therapeutics salgono dopo la collaborazione con Bristol Myers Squibb

Janux e Bristol Myers Squibb collaborano su terapia attivata dal tumore